AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02969473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle.
Study NCT02094573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets
Study NCT01169389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection
Description: Durolane, one vial
Study NCT01169389 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular injection of 0.5% Bupivacaine
Study NCT01650389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Study NCT01650389 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candin
Study NCT01650389 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine SSI
Description: All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination.
Study NCT01650389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Vaccine SSI
Description: All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination.
Study NCT00607906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 immediate release capsule
Description: SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
Study NCT00607906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-756050 modified release capsule
Description: SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
Study NCT00607906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo capsules.
Study NCT03975673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hip replacement
Description: Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
Study NCT01284400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based disease management
Description: Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
Study NCT01136824 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms
Study NCT04901559 — intervention group
Intervention type: PROCEDURE
Intervention: Graft type at ACLR
Description: The choice of graft at primary ACL Reconstruction
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: given intravenously or orally
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clofarabine
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: given intravenously
Study NCT00545441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)
Description: Surgical placement of the Surgisis AFP is performed under general anesthesia.
Study NCT00545441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flap
Description: Advancement flap surgery is performed; no anal fistula plug is placed
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: aldesleukin
Description: given subcutaneously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: given intrathecally or intravenously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: given orally
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: given intrathecally or intravenously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teniposide
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Description: given intravenously
Study NCT01700946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: natural killer cell infusion
Description: undergo allogeneic natural killer cell infusion
Study NCT01700946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: correlative studies
Study NCT01700946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Description: given intrathecally
Study NCT01700946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic hematopoietic stem cell transplantation
Description: undergo allogeneic HSCT
Study NCT01700946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT01168934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
Study NCT01168934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
Study NCT02211989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 14332 CL
Study NCT02211989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04163276 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F FDG PET exam
Description: All patients have received 18F-FDG PET/CT in nuclear medicine
Study NCT02540239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2L PEG
Study NCT02540239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG+simethicone
Study NCT03750916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study NCT03753126 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 4-dimensional volume-rendered computed tomography
Study NCT01351129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: 150-mg immediate release tablet (single dose)
Study NCT01351129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: 150-mg modified release capsule, short duration (single dose)
Study NCT01351129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 3
Description: 150-mg modified release capsule, long duration (single dose)
Study NCT02677805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
Study NCT02677805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
Study NCT02677805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A - Open Label
Description: Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
Study NCT05002101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc
Description: The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
Study NCT05002101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
Study NCT00973531 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Autotitrating Positive Airway Pressure (APAP)
Description: Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
Study NCT00973531 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Split Titration Polysomnogram
Description: Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
Study NCT03932838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and radiologic evaluation
Description: Follow up post surgery: clinical and radiologic evaluation
Study NCT00828581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin
Study NCT00756652 — intervention group
Intervention type: DEVICE
Intervention: Mentor Silicone Gel-Filled Breast Implants
Study NCT00756652 — intervention group
Intervention type: DEVICE
Intervention: Saline Breast Implants
Study NCT02564952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
Study NCT02564952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
Study NCT03308123 — intervention group
Intervention type: OTHER
Intervention: Observational study, not interventional
Description: Not an intervention study
Study NCT02341209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate
Description: Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
Study NCT03262519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computer based neurocognitive testing
Description: Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
Study NCT02977494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
Study NCT02977494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02977494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01288417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 10 days of boceprevir 800mg TID
Study NCT04884126 — intervention group
Intervention type: PROCEDURE
Intervention: dental implant placement
Description: The time of dental implant surgery
Study NCT01288417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: raltegravir 400mg single dose
Study NCT01288417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir 400mg single dose
Study NCT01125358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally, twice daily for up to 7 weeks of treatment
Study NCT04304690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: 2 blood samples at T0 and 3 months
Study NCT02048956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy intervention
Description: Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
Study NCT02048956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard exercises of hydrotherapy
Study NCT00592449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for insomnia
Description: During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
Study NCT00592449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral desensitization treatment for insomnia
Description: The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
Study NCT03335657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBPT
Description: The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
Study NCT03335657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Treatment
Description: Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
Study NCT00907270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol: 4,000 IU/day and 400 IU/day
Study NCT00907270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol: 4,000 IU/day and 400 IU/day
Study NCT02323464 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for colorectal cancer
Description: Includes open and minimally invasive surgery for colon- and rectal cancer
Study NCT02323464 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Description: This is a control group from the population. They are not scheduled for surgery
Study NCT02091518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MR Screening Questionnaire
Description: All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
Study NCT02091518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging Acquisition and Analysis
Description: MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
Study NCT03424421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subscapular sling
Description: semitendinosus subscapular sling procedure
Study NCT00694460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three 1 mL doses of Rabies vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
Study NCT00694460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three 0.5 mL doses of Rabies vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
Study NCT00694460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three 0.1mL doses of Rabies Vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
Study NCT00694460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two 0.1mL doses of Rabies vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
Study NCT00694460 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Two doses of JE vaccine
Description: Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
Study NCT02889081 — intervention group
Intervention type: OTHER
Intervention: maternal biological folate level
Description: supplementation status and serum level
Study NCT02889081 — intervention group
Intervention type: OTHER
Intervention: maternal biological Vitamin D level
Description: supplementation status and serum level
Study NCT01187238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
Study NCT04285606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-led rehab with short immobilization
Description: Short immobilization followed by patient-led shoulder rehab
Study NCT03843359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3745417
Description: GSK3745417 will be administered.
Study NCT01125358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, twice daily for up to 7 weeks of treatment
Study NCT03843359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT01856257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte Globulin (Rabbit)
Description: The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
Study NCT03970135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
Study NCT01856257 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte Globulin (Rabbit)
Description: The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.